PR Newswire
SAN DIEGO, July 26, 2018
SAN DIEGO, July 26, 2018 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will be
presenting at the Canaccord Genuity 38th Annual Growth Conference in Boston on
Thursday, August 9 at 12:00 p.m. ET/9:00 a.m.
PT. Laurie Stelzer, senior vice president and chief financial officer, will provide a
corporate overview.
A webcast of the presentation can be accessed through the "Investors" section of www.halozyme.com, and a recording will be made available for 90 days following the
event. To access a live webcast, please visit Halozyme's website approximately 15 minutes prior to the presentation to register
and download any necessary audio software.
About Halozyme
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies
that target the tumor microenvironment. Halozyme's lead proprietary program, investigational drug pegvorhyaluronidase alfa
(PEGPH20), applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug
therapies to the tumor in animal models. PEGPH20 is currently in development for metastatic pancreatic cancer, non-small cell
lung cancer, gastric cancer, metastatic breast cancer and has potential across additional cancers in combination with different
types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships
with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb and Alexion
for its ENHANZE® drug delivery technology. Halozyme is headquartered in San Diego.
For more information visit www.halozyme.com.
Contacts:
Chris Burton
858-704-8352
ir@halozyme.com
View original content with multimedia:http://www.prnewswire.com/news-releases/halozyme-therapeutics-to-participate-in-upcoming-healthcare-conference-300687002.html
SOURCE Halozyme Therapeutics, Inc.